Treatment of dyslipidemia in patients with diabetes mellitus.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue
Abstract
The article reviews the key aspects of pathophysiology of diabetic dyslipidemia, its treatment and associated risk of cardiovascular complications. It examines the difference in lipidmetabolism between type 1 and type 2 diabetes mellitus. The diagnostic values of particular lipid abnormalitiesas risk predictors for cardiovascular events are analyzed. Guidelines on hypolipemic treatment in diabetes are summarized and commented on. Standard and newly introduced methods as well as new opportunities of hypolipemic treatment are presented.
Authors and Affiliations
Witold Pikto-Pietkiewicz, Katarzyna Wołkowska, Tomasz Pasierski
Keywords
Related Articles
- EP ID EP144322
- DOI -
- Views 145
- Downloads 0
Role of nitric oxide in the development of tolerance to diazepam-induced motor impairment in mice.
Chronic treatment with the benzodiazepines is well known to produce tolerance, which has been extensively documented to be attributed to modifications in the gamma-aminobutyric acid (GABA)ergic neurotransmission. However...
Glyburide for the treatment of gestational diabetes mellitus.
Insulin is the traditional treatment for gestational diabetes mellitus (GDM) unresponsive to dietary interventions. Until recently, oral hypoglycemic drugs had been contraindicated due to concerns regarding teratogenicit...
Modification of local anesthetic-induced antinociception by fentanyl in rats.
In clinical practice, using the lowest doses of drugs for anesthesia or analgesia is the main goal. Opioid combinations with local anesthetics can be preferable for achieving adequate anesthesia or analgesia. The primary...
Non-neutral nonsynonymous single nucleotide polymorphisms in human ABC transporters: the first comparison of six prediction methods.
Nonsynonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptibility to disease and altered drug/xenobiotic...
New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation.
Background: Our previous studies in a group of arylpiperazine derivatives of 1,3-dimethyl-3,7-dihydro-purine-2,6-diones, aimed at chemical diversification of the purine-2,6-dione by introduction of hydrophobic substituen...